All News
@Bweber04 on recurrent pericarditis especially some seen in our lupus population
IL-1 inhibition with Rilonacept really redefining treatment success and altering the typical treatment algorithm
@RheumNow #ACR23 https://t.co/Ey1DN8eSXT
Robert B Chao, MD ( View Tweet)
Later today at #ACR23 at 4pm
See Ab#2545 on IV secukinumab for AxSpA
Read about it now on @RheumNow:
https://t.co/s9IinpVxgR
Eric Dein ( View Tweet)
RheumNow’s expanded coverage of #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
Watch: Ultrasound for PsA Stratification: Are We There Yet?
Dr. Aurelie Najm reports live from #ACR23
https://t.co/TnDVbKXcd4 https://t.co/RTbjL2wbUj
Dr. John Cush RheumNow ( View Tweet)
Interesting counterpoint to a tweet from a few days ago re:black box warning for JAKs
No change in utilization rates post black box... maybe people had already baked this into the cake by then?
@RheumNow #ACR23 Abstr 2142 https://t.co/K9cWbRSWV6
Mike Putman EBRheum ( View Tweet)
Amazing & thoughtful poster re:protocol violates in TICOSPA trial
51.2% of pts violated T2T protocol at least once... but did not impact primary outcome
Good baseline for future "strategy" style pragmatic trials
@RheumNow #ACR23 #ACRBest Abstr2201 https://t.co/FhctgFNdNP
Mike Putman EBRheum ( View Tweet)
#ACR23 Late-Breaking Abstr#L09 In a crowded market, you’ve got to stand out. Phase 2 RCT of LNK01001, a highly selective JAK1-i in China: improvement in ACR 20,50,70 vs PBO at WK12. Those in PBO who didn’t meet ACR20 improved after receiving Tx. Very low infections @RheumNow https://t.co/ZbJFNHOtFT
Md Yuzaiful Md Yusof ( View Tweet)
A#L09 #ACR23 @RheumNow
New JAK! LNK01001
Chinese pts with mod-severe RA, csDMARD failures
12mg/24mg/PBO: W12: ACR20 60/73/31%, ACR50 40/42/9, ACR70 12/21/2%
Stat signif diff reached at wk 1 for ACR20!
Improved DAS28, HAQ-DI
Wk24 ext: 91% remain in ACR 20
AEs: HLD noted https://t.co/RXOMzxGOTy
Eric Dein ( View Tweet)
CV Events in AS by Rx
A#L11 @RheumNow #ACR23
43K pts from Korean data
Rates of incident MI or CV:
18.7 per 10,000 py in non-bDMARD pt
8.9 in TNF
12.9 in IL-17
TNFi reduced risk of CVD HR 0.7, not signif for IL-17
Supports idea of TNFi giving a cardioprotective effect?
#ACRBest https://t.co/SvVVDSU23z
Eric Dein ( View Tweet)
ARTIC REWIND: To taper or not?
A#L07 #ACR23 @RheumNow
RA pts taper TNFi in stable remission
No taper group: 85% flare free in 3 yrs
Taper grp: only 25%
Lower Boolean 2.0 Remission rates
Don't taper off a good thing! https://t.co/KnJrEfVFkV
Eric Dein ( View Tweet)
Lessons for #CVD in #inflammatory #rheumatic #diseases #ACR23 @RheumNow @ACRheum #ACRbest
-Negative #coronary #calcification doesn’t r/o presence of #microvascular #dysfunction
- work w #cardiologist for@proper@imaging for #Dx
-for #CAD or #pericarditis #Colchicine is GOOD https://t.co/dMO1FpoA2a
Janet Pope ( View Tweet)
Excellent session: Navigating CV risk for #inflammatory #arthritis - view from #cardiology #ACR23 14T118 @RheumNow @ACRheum https://t.co/WKhh0TonE8
Janet Pope ( View Tweet)
#ACR23 Late-Breaking Abstr#L14 Which team are you on? IL5-i or IL5-receptor-i #EGPA. Phase 3 H2H RCT showed similar efficacy btw Mepolizumab and Benralizumab, with more pts fully tapering off GC at WK52 favouring BENRA. Rapid reduction in Eosinophils too @RheumNow #ACRBest https://t.co/cXhSS80mA2
Md Yuzaiful Md Yusof ( View Tweet)
Is #cardiology now a specialty like #rheumatology with bDMARDs? Many pathways discussed for CVD in #rheumatoid #arthritis. And biologics for lowering lipids too! #ACR23 @ACRheum @RheumNow 14T118. More overlap of pts over time! https://t.co/blv5GmHTGe
Janet Pope ( View Tweet)
A#L06 #ACR23 @RheumNow
Refractory juv SSc 6m-2y after autolog Stem Cell Tx - 5 patients
HAQ VAS improved 75% (48-99%)
All: mRSS MCID by 6 mo, 87% aver improvement, sustained at 2y
GI: GIT mean 55% improvement, 1 unchanged
FVC stable, DLCO improv >10% in 2, 5-10% in 2
#ACRBest https://t.co/cc6YToVEO5
Eric Dein ( View Tweet)
#Cardiology imaging has advanced - work with #cardiologists to know what to order - esp for our Pts w #inflammatory #diseases #ACR23 @RheumNow @ACRheum 14T118 https://t.co/RuHJuy7Dh2
Janet Pope ( View Tweet)
Speaking of influencing in rheumatology… @RheumNow and @anisha_dua know best! #ACR23 #Facesofrheumatology https://t.co/EsppP3FPoX
Adela Castro AdelaCastro222 ( View Tweet)
MANDARA: Benralizumab v Mepolizumab in EGPA
A#L14 #ACR23 @RheumNow
P3, 52w RCT, 140 pts
Remission rate: 59% Ben, 56.5% Mep
Relapse rate 30% in both
86% Ben, 74% Mep had reduction of GC dose 50%+, 41% v 26% tapered off
SAEs: 6% Ben, 13% Mep
Concl: Non-inferiority of Ben v Mep https://t.co/mSIFsDq8eL
Eric Dein ( View Tweet)
I continue to be underwhelmed by nintedanib, esp in RA-ILD
Data from INBUILD-ON, f/u study to the INBUILD basket trial
Persistent loss of FVC... wonder how pts would have done had they received an RA-active DMARD?
Need H2H vs TNFs & real DMARDs
@RheumNow #ACR23 Abstr 2158 https://t.co/56PgC6Uc67
Mike Putman EBRheum ( View Tweet)
Real-World Issues in AxSpA: Treatment Intensification, Pregnancy
Dr. Rabab Nezam El-Din and colleagues explored patient- and disease-related determinants that were associated with treatment intensification among axSpA patients w/ high disease activity.
https://t.co/vZ66hsErBI https://t.co/pN8JZAEcqv
Dr. John Cush RheumNow ( View Tweet)